NFATC2-deficient mice are protected against the development of anti-ASNase antibodies and ASNase hypersensitivity. (A) Schematic representation of ASNase immunization and challenge protocol. (B) Immunized NFATC2-deficient (KO) mice are protected against developing hypothermia when challenged with ASNase. (C-E) KO mice have lower mMCP-1 levels (C), higher ASNase drug or activity levels (D), and fewer detectable ASNase immune complexes (ICs) (E) in plasma after the ASNase challenge. (F-J) Plasma antibody levels were assessed after immunization and KO mice developed lower anti-ASNase total immunoglobulin G (IgG) (F), anti-ASNase IgG1 (G), anti-ASNase IgE antibody responses (H-I), and total IgE (J) relative to WT mice. *P < .05; **P < .01; ****P < .0001. alum, aluminium hydroxide adjuvant; AUC, area under the curve; i.p., intraperitoneal; MFI, mean fluorescence intensity; OD, optical density.